influenza virus entry

MBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.

CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). It interferes with the hemagglutinin (HA)-mediated fusion process.

IAV-IN-2 (Compound MC-22) inhibits influenza A virus (IAV) by preventing its entry into host cells via clathrin-mediated endocytosis (CME).

VF-57a (Compound 23) is an inhibitor of Influenza A virus (IAV) fusion. It exhibits potent antiviral activity against the real A/H1N1 virus, with EC50 values of 0.92 μM for the A/H1N1 PR8 strain and 0.31 μM for the A/H1N1 Virg09 strain. VF-57 significantly inhibits cell entry of HA-mediated A/H1N1 and A/H5N1 pseudoviruses and prevents HA refolding at pH 5.2. VF-57a is utilized in IAV infection research.

CL385319 is a potent inhibitor of H5N1 avian influenza A virus infection by blocking viral entry. CL-385319 is effective in inhibiting infection of highly pathogenic H5N1 influenza A virus in Madin-Darby Canine Kidney (MDCK) cells with an IC50 of 27.03±2.

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Ribavirin-13C5 is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin (T0684) is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers.

RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) with an EC50 of 2.92 μM and influenza A virus (IAV) with an EC50 of 1.90 μM. RSV/IAV-IN-3 significantly inhibits luciferase activity in a dose-dependent manner (EC50: 3.89 μM) and suppresses IAV infection, RdRp activity, as well as post-entry replication of IAV and RSV.

Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that specifically targets influenza A virus by binding the highly conserved stem region of the viral haemagglutinin protein, Gedivumab prevents haemagglutinin maturation and blocking membrane fusion during viral entry within the intranucleosomal environment, and it is extensively applied in influenza A virus infection studies and antiviral therapeutic research.

Antiviral agent 43 (compound 16) serves as a potent, orally active inhibitor of influenza A virus entry, demonstrating efficacy by inhibiting the replication of the influenza A strains VH04-H5N1 and PR8-H1N1 with EC50 values of 240 nM and 72 nM, respectively [1].

MI-1904 is an inhibitor of matriptase/TMPRSS2, exhibiting antiviral activity against influenza virus (influenza virus) strains H1N1 and H9N2. This compound prevents the cleavage of viral surface glycoproteins, thereby inhibiting the binding of the virus to host cell receptors, which effectively blocks viral entry and replication.

Foryshiyanine A is a triterpenoid alkaloid with notable biological activities. It exhibits anti-inflammatory properties by inhibiting β-glucuronidase release from rat polymorphonuclear leukocytes. Additionally, Foryshiyanine A demonstrates antiviral activity, with an EC50 value of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 value of 7.3 μM against the influenza A H1N1 virus. It reduces viral load by interfering with viral replication and entry, making it useful for studying inflammation and infection.